【ChiCTR2200061817】Clinical Training Dosage of Robotic Exoskeleton Assisted Gait Training for Improvement of Gait Parameters, Walking Performance, Balance and Health-related Benefits in Patients with Chronic Stroke: a Randomized Control Trial
ChiCTR2200061817
尚未开始
/
/
/
2022-07-03
/
/
Stroke
Clinical Training Dosage of Robotic Exoskeleton Assisted Gait Training for Improvement of Gait Parameters, Walking Performance, Balance and Health-related Benefits in Patients with Chronic Stroke: a Randomized Control Trial
Clinical Training Dosage of Robotic Exoskeleton Assisted Gait Training for Improvement of Gait Parameters, Walking Performance, Balance and Health-related Benefits in Patients with Chronic Stroke: a Randomized Control Trial
To evaluate the most efficient clinical training dosage of powered robotic exoskeleton assisted gait training for improvement of gait parameters, walking performance, balance and health-related benefits in patients with chronic stroke.
整群随机分组
其它
Randomisation sequence to be generated by online randomisation generator
/
Institutional Development Grant
/
7
/
2022-06-20
2023-06-20
/
Participants will be recruited if they fulfill the following inclusion criteria: 1. Currently in the chronic phase of stroke (>= 6 months post stroke); 2. Able to walk with supervision; 3. Body weight equals to or is less than 100 kg; 4. There are no severe deformities, spasticity or restricted motion in the legs; 5. Able to follow verbal instructions.；
请登录查看Not cooperative or have unstable medical conditions or musculoskeletal diseases which affect mobility.；
请登录查看Caritas Institute of Higher Education
/
Caritas Institute of Higher Education的其他临床试验
- Randomized Controlled Trail: Medical Assessment and Response by Small-unmanned-aerial-system (MARS)
- Clinical Training Dosage of Robotic Exoskeleton Assisted Gait Training for Improvement of Gait Parameters, Walking Performance, Balance and Health-related Benefits in Patients with Chronic Stroke: a Randomized Control Trial
Caritas Institute of Higher Education的其他临床试验
最新临床资讯
-
护肾先锋 | 逆转“不可逆”：88岁高龄“糖尿病肾病”患者，精准诊治重获新生
广东省中医院2026-08-14
-
破除临床痛点，医院原创冠脉微循环无创诊疗技术获全球权威认可
西南医院2026-08-14
-
bioSeedin柏思荟2026-08-14
-
迈同生物2026-08-14
-
COD医材汇2026-08-14
-
九源基因2026-08-14
-
丁香园 Insight 数据库2026-08-14
-
辐联科技Full Life Technologies2026-08-14
-
茵诺医药2026-08-14
-
优赛生命2026-08-14
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-14
-
2026-08-14
-
2026-08-14
-
摩熵咨询 20 8
-
摩熵咨询 34 28
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-14
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 37
-
摩熵咨询 28 39
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29